United Kingdom: These 5 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: United Kingdom Patent 410,712

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries.

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: United Kingdom Patent 410,712

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: United Kingdom Patent 411,378

CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.

This drug has forty patent family members in thirty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: United Kingdom Patent 411,384

QNASL is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in thirty-two countries.

See drug price trends for QNASL.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: United Kingdom Patent 2,414,187
Patent Title: A dispensing apparatus having a dosage counter and a cog for use in the counter

QNASL is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in thirty-two countries.

See drug price trends for QNASL.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

Generic name: fluticasone furoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2024
Generic Entry Controlled by: United Kingdom Patent 418,278

ARNUITY ELLIPTA is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.

This drug has one hundred and sixteen patent family members in twenty-seven countries. There has been litigation on patents covering ARNUITY ELLIPTA

See drug price trends for ARNUITY ELLIPTA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the fluticasone furoate profile page.